$347.45 5.5%
MDGL Stock Price vs. AI Score
Data gathered: November 22

AI Score



Sign up to see AI score

Brand Score Sign up
Employment Score Sign up
User Growth Score Sign up
Fundamental Score Sign up

AI Stock Analysis - Madrigal Pharmaceuticals (MDGL)

Analysis generated June 25, 2024. Powered by Chat GPT.

Madrigal Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of cardiovascular and metabolic diseases. The company leverages its expertise in small molecule drug discovery to develop novel treatments targeting unmet medical needs. Madrigal's primary mission is to develop therapeutic candidates that can transform the standard of care for diseases with serious health impacts.

Read full AI stock Analysis

Stock Alerts - Madrigal Pharmaceuticals (MDGL)

company logo Madrigal Pharmaceuticals | November 22
Price is up by 5.4% in the last 24h.
company logo Madrigal Pharmaceuticals | November 19
Price is up by 5.1% in the last 24h.
company logo Madrigal Pharmaceuticals | November 18
Price is up by 5.3% in the last 24h.
company logo Madrigal Pharmaceuticals | November 15
Price is down by -5.7% in the last 24h.

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States.


Madrigal Pharmaceuticals
Price $347.45
Target Price Sign up
Volume 537,170
Market Cap $6.92B
Year Range $193.33 - $354.85
Dividend Yield 0%
Analyst Rating 83% buy
Industry Biotechnology

In the news


Financial performance View All

Revenue Cost of Revenue Gross Profit Net Income ebitda EPS
Q3 '2458M108M-49M-107M-116M-4.920
Q2 '2411M105M-94M-152M-162M-7.100
Q1 '24081M-81M-148M-152M-7.380
Q4 '23047M-47M-112M-117M-5.680
Q3 '23028M-31M-99M-99M-5.340

Insider Transactions View All

Levy Richard S filed to sell 11,012 shares at $304.3.
November 5 '24
Levy Richard S filed to sell 11,312 shares at $302.2.
November 5 '24
Levy Richard S filed to sell 12,112 shares at $301.2.
November 5 '24
Levy Richard S filed to sell 13,212 shares at $300.1.
November 5 '24
Sibold William John filed to sell 55,887 shares at $243.8.
September 11 '24

What is the Market Cap of Madrigal Pharmaceuticals?

The Market Cap of Madrigal Pharmaceuticals is $6.92B.

What is the current stock price of Madrigal Pharmaceuticals?

Currently, the price of one share of Madrigal Pharmaceuticals stock is $347.45.

How can I analyze the MDGL stock price chart for investment decisions?

The MDGL stock price chart above provides a comprehensive visual representation of Madrigal Pharmaceuticals' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Madrigal Pharmaceuticals shares. Our platform offers an up-to-date MDGL stock price chart, along with technical data analysis and alternative data insights.

Does MDGL offer dividends to its shareholders?

As of our latest update, Madrigal Pharmaceuticals (MDGL) does not offer dividends to its shareholders. Investors interested in Madrigal Pharmaceuticals should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.

What are some of the similar stocks of Madrigal Pharmaceuticals?

Some of the similar stocks of Madrigal Pharmaceuticals are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.

.
The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.
About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.



App download

Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.

© 2024 AltIndex. All rights reserved.